To meet the challenge to human health posed by obesity, a better understanding of the regulation of feeding is essential. Medications targeting 5-hydroxytryptamine (5-HT; serotonin) 2C receptors (htr2c; 5-HT 2C R) improve obesity. Here we probed the functional significance of 5-HT 2C Rs specifically within the brainstem nucleus of the solitary tract (5-HT 2C R NTS ) in feeding behavior. Selective activation of 5-HT 2C R NTS decreased feeding and was sufficient to mediate acute food intake reductions elicited by the 5-HT 2C R agonist obesity medication lorcaserin. Similar to pro-opiomelanocortin neurons expressed within the hypothalamic arcuate nucleus (POMC ARC ), a subset of POMC NTS neurons co-expressed 5-HT 2C Rs and were activated by 5-HT 2C R agonists. Knockdown of POMC NTS prevented the acute appetite-suppressive effect of lorcaserin, whereas POMC ARC knockdown prevented the full anorectic effect. These data identify 5-HT 2C R NTS as a sufficient subpopulation of 5-HT 2C Rs in reducing food intake when activated and reveal that 5-HT 2C R agonist obesity medications require POMC within the NTS and ARC to reduce food intake.
In Brief
The brain serotonin pathway regulates appetite and body weight. D'Agostino, Heisler et al. show that the anti-obesity 5-HT 2C R agonist lorcaserin targets both the POMC circuitry of the hypothalamus and the brainstem nucleus of the solitary tract (5-HT 2C R NTS ) to mediate appetite suppression.
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INTRODUCTION
As demonstrated 40 years ago, brain 5-hydroxytryptamine (5-HT; serotonin) is a significant regulator of appetite and body weight (Breisch et al., 1976) . Targeting this neurochemical machinery, medications increasing 5-HT bioavailability were developed to treat obesity. However, increasing 5-HT activity at peripheral 5-HT receptors contributed to side effects that led to the withdrawal of medications such as d-fenfluramine in the 1990s and sibutramine in the 2000s (Burke and Heisler, 2015) . Efforts to delineate 5-HTRs mediating 5-HT's therapeutic effects on food intake revealed the 2C receptor subtype (Htr2cr, 5-HT 2C R) as the principal mediator (Tecott et al., 1995; Williams et al., 2011) . The clinical significance of this discovery is underscored by a new obesity medication, the 5-HT 2C R agonist, lorcaserin, which was recently launched in the United States (Aronne et al., 2014; Smith et al., 2010) . 5-HT 2C Rs are widely distributed within the brain where they act to modulate a diverse array of behaviors and physiological processes (Burke and Heisler, 2015; Julius et al., 1988) . Of the neurochemically defined cells expressing 5-HT 2C Rs, it is a subpopulation of neurons within the arcuate nucleus of the hypothalamus (ARC) that co-express the precursor polypeptide pro-opiomelanocortin (POMC) that have been proposed to be a principal mediator of 5-HT 2C R's effects on metabolic functions (Berglund et al., 2013; Burke et al., 2017; Doslikova et al., 2013; Heisler et al., 2002; Xu et al., 2010) . However, anorectic doses of 5-HT 2C R agonists have been shown to increase markers of neuronal activity in caudal brainstem regions, including the nucleus of the solitary tract (NTS) Stark et al., 2006) . Although the NTS is a brainstem structure known to be a key regulatory center for the integration of food related signals of both peripheral and central origin (Fan et al., 2004; Grill and Hayes, 2009; Zhan et al., 2013) , no direct functional assessment of 5-HT 2C Rs in this brain region has been undertaken. Here we probed the functional significance of 5-HT 2C Rs within the NTS, their contribution to the therapeutic effect of 5-HT 2C R agonist obesity medications, and the mechanism underpinning their appetite-reducing effect via exclusive action within the NTS.
RESULTS
Selective 5-HT 2C R NTS Neuron Activation Decreases Food Intake
To determine whether 5-HT 2C R-expressing NTS (5-HT 2C R NTS )
neurons play a role in appetite control, we first employed the chemogenetic designer receptors exclusively activated by designer drugs (DREADDs; Armbruster et al., 2007) approach to specifically express G q -coupled (hM3D q ) or G i -coupled (hM4D i ) designer receptors in 5-HT 2C R NTS neurons. To target 5-HT 2C R NTS neurons, we stereotactically delivered Cre-dependent adeno-associated viruses (AAVs) encoding designer receptor hM3D q or hM4D i into the NTS of 5-HT 2C R Cre mice (Burke et al., , 2017 Marcinkiewcz et al., 2016) Figure 1C) . A degree of spread was observed in adjacent regions following amplification of mCherry signal with immunohistochemistry (Figure 1C) . Following treatment with designer drug clozapine-Noxide (CNO; 1 mg/kg, intraperitoneally [i.p.]), c-fos immunoreactivity (FOS-IR; a surrogate marker of neuronal activation) was observed within the NTS of 5-HT 2C R NTS -hM3D q mice. In
5-HT 2C R
NTS -hM3D q mice that had been fasted overnight to decrease baseline FOS-IR, quantification analysis revealed that approximately 76.4% ± 3.7% of mCherry-positive NTS cells expressed FOS-IR following CNO treatment whereas less than 1% expressed FOS-IR following saline treatment ( Figure 1C ). Consistent with these in vivo data, in ex vivo NTS slices, bath application of CNO (10 mM) increased the firing frequency of 5-HT 2C R NTS -hM3D q -expressing neurons (n = 5/5; Figure 1D ).
These data indicate that CNO allows remote chemical control of 5-HT 2C R NTS neuronal activity in 5-HT 2C R NTS -hM3D q -expressing mice. We next examined the effect of CNO on feeding behavior. CNO (1 mg/kg, i.p.) significantly reduced the first 5 hr of ad libitum dark cycle chow intake compared with saline treatment in 5-HT 2C R NTS -hM3D q mice ( Figure 1E ). ). We achieved this using a reversible 5-HT 2C R null line, in which expression of Htr2cr is prevented by a loxP-flanked transcriptional blocker (Xu et al., 2008) . The expression of Htr2cr was site-specifically reactivated via stereotactic delivery of an AAVexpressing Cre recombinase (AAV-Cre) into the NTS/DMV, which removes the transcriptional blocker (Figures 2A and 2B Figure 2E ). (Nonogaki et al., 2003; Xu et al., 2008) ; an effect that failed to normalize following post-developmental re-expression of the 5-HT 2C R exclusively within the NTS/DMV ( Figure S2A ). Further analysis of energy balance revealed no difference in daily, nocturnal, or diurnal energy expenditure between genotypes ( Figures S2B and S2C ). We were unable to detect the predicted increase in ad libitum chow intake ( Figure S2D ) or chow intake following an overnight fast in 5-HT 2C R KO mice ( Figure S2E ), which may be related to the previously reported variability in the magnitude of hyperphagia on a chow diet with age in 5-HT 2C R KO mice (Wade et al., 2008 (Burke et al., 2014; Fletcher et al., 2009) has a significant impact on feeding behavior. These data also reveal that 5-HT 2C Rs expressed within the NTS/DMV are sufficient to mediate acute therapeutic effects of a medication currently in clinical use to treat obesity, thereby highlighting a specific subset of 5-HT 2C Rs that may be exploited for future obesity medication development.
5-HT 2C R Agonists Directly Activate POMC NTS Cells
We next interrogated the neurochemical phenotype of 5-HT 2C R NTS cells to probe the mechanism through which 5-HT 2C R NTS -mediated effects on appetite are achieved. Though POMC neurons within the ARC have been proposed to be a primary mediator of 5-HT 2C R's effects on metabolic functions (Berglund et al., 2013; Burke et al., 2014 Burke et al., , 2017 Doslikova et al., 2013; Heisler et al., 2002; Xu et al., 2010) , a smaller and less well characterized population of POMC expressing neurons reside within the caudal aspect of the NTS (POMC NTS ), a region receiving inputs from vagal afferent fibers that transmit mealrelated information from the gastrointestinal system (Appleyard et al., 2005; Fan et al., 2004; Joseph et al., 1983; Zhan et al., 2013) . We thus hypothesized that POMC NTS is a functional component of 5-HT 2C R NTS -mediated hypophagia.
To visualize anatomical expression, we utilized Pomc DsRED reporter mice (Hentges et al., 2009 ) and fluorescent in situ hybridization to label endogenous 5-HT 2C R mRNA. Although more than one-third (38.2% ± 1.3%) of POMC NTS cells express 5-HT 2C R mRNA, POMC NTS neurons represent only a small (approximately 4%) subset of the total NTS 5-HT 2C R mRNA-expressing population ( Figure 3A ). Next, to evaluate the impact of 5-HT 2C R activation on POMC NTS neuronal activity, we performed whole-cell electrophysiological recordings in Pomc DsRED NTS slices.
Consistent with the anatomical co-expression profile, 45.5% (10/22) of Pomc DsRED cells were responsive to 5-HT (10 mM), the endogenous 5-HT 2C R agonist (Figures 3B and 3C) . A similar proportion of responders was observed following application of 5-HT 2C R agonists lorcaserin (20 mM) and WAY161,503 (20 mM), with 47.1% (8/17) and 50% (11/22) of Pomc DsRED cells responding, respectively (Figures 3B and 3C) . All responses were characterized by depolarization and commencement/enhancement of action potential discharge. These effects were independent of action potential-dependent synaptic transmission, as depolarizations endured in the presence of 500 nM tetrodotoxin (TTX) (5-HT, 13.2 ± 3.8 mV, n = 7; lorcaserin, 11.7 ± 3.6 mV, n = 7; WAY161,503, 12.8 ± 2.7 mV, n = 8; Figure 3C ), indicating that 5-HT and 5-HT 2C R agonists directly activate POMC NTS cells via a post-synaptic mechanism. 5-HT and 5-HT 2C R agonists induced a similar degree of depolarization and activated a similar percentage of POMC NTS cells ( Figure 3D ). These data reveal that 5-HT 2C Rs are anatomically positioned to increase the activity of a subset of POMC NTS cells.
To examine the post-synaptic ionic mechanisms underpinning the excitatory effects of 5-HT and lorcaserin, we recorded POMC NTS neurons in a voltage clamp (VC) and in the presence of TTX. At a holding potential of À60 mV, application of 5-HT (10 mM) induced a reversible inward current of À23.1 ± 2.5 pA (n = 10; Figure 4A ). The current-voltage relationship of I 5-HT was examined using VC ramps, which drove the membrane potential from À120 mV to 0 mV at a rate of 45.7 mV s À1 ( Figure 4B ; n = 10).
The digital subtraction of the ramp in control from the ramp at the peak of the response revealed I 5-HT to be outwardly rectifying and to reverse at À27.0 ± 3.6 mV ( Figure 4C ; n = 10). Likewise, lorcaserin (20 mM) induced an inward current of À15.5 ± 2.5 pA (n = 12; Figure 4D ) that was shown to be outwardly rectifying and to reverse at À24.6 ± 2.9 mV ( Figures 4E and 4F ). These data illustrate that 5-HT and lorcaserin excite POMC NTS neurons via the activation of a post-synaptic, mixed cationic current. This mechanism is consistent with that observed for 5-HT 2C R activation of POMC ARC neurons (Sohn et al., 2011 (Heisler et al., 2002; Lam et al., 2008) . Earlier transgenic approaches have revealed that the subset of 5-HT 2C Rs that are necessary and sufficient for 5-HT 2C R agonists to reduce food intake are co-expressed with POMC (Berglund et al., 2013; Xu et al., 2008) . These approaches manipulate the expression of the receptor, not POMC production. We aimed to determine the function of POMC in lorcaserin's anorectic effect. ) littermates were treated with saline or lorcaserin (7 mg/kg, i.p.) at the onset of the dark cycle and ad libitum home cage chow intake was measured 1, 3, and 6 hr later. As expected, Pomc WT mice treated with lorcaserin significantly reduced food intake compared with saline-treated littermates at each time point ( Figure 5A ). However, lorcaserin did not have a significant effect on food intake at any of these time points in Pomc NEO mice compared with saline-treated littermates ( Figure 5B ). These results were replicated in further cohorts of Pomc NEO and Pomc WT littermates using a within-subjects experimental design (data not shown). These data reveal that brain POMC is required for lorcaserin to promote its effects on food intake. (Doudna and Charpentier, 2014; Hsu et al., 2014) . Specifically targeted by synthetic guide RNA (sgRNA) sequences, Cas9-induced double-stranded breaks typically result in frameshifting insertion/deletions (indels) owing to the action of non-homologous end-joining (NHEJ) DNA repair mechanisms, leading to disruption of the encoded protein.
Following an in vitro screening of selected sgRNAs targeting the third exon of the Pomc gene, Cas9-induced indels at the predicted positions were detected using a T7 endonuclease I assay ( Figure 6A ). Two active sgRNAs were cloned into an AAV vector that also expressed eGFP to enable site-specific brain delivery (Swiech et al., 2015 ) were then stereotactically injected into the ARC ( Figure 6B ). Quantitative analysis of hypothalamic a-MSH content revealed Pomc ARC-CRISPR mice had an approximately 60% reduction in a-MSH ( Figure 6C ). To control for the occurrence of CRISPR/Cas9-induced indels, we implemented a method allowing ex vivo detection of DNA heteroduplexes. This is a widely used proxy of indel occurrence in vitro. Genomic DNA from Pomc ARC-CRISPR and Pomc ARC-WT mice was extracted and the third exon of the Pomc gene was amplified by PCR. Subsequent PAGE analysis revealed that DNA heteroduplexes were exclusively in samples obtained from the mediobasal hypothalamus in Pomc ARC-CRISPR mice. DNA heteroduplexes were not found in the hypothalamus of Pomc ARC-WT mice ( Figure 6D ). Behaviorally, Pomc ARC-CRISPR mice displayed phenotypes consistent with reduced POMC ARC function, including hyperphagia following food deprivation ( Figure 6E ) and greater operant responding for palatable food ( Figure 6F ). Next, we assessed the role of POMC ARC in lorcaserin's effects on food intake. As expected, lorcaserin significantly reduced ad libitum dark cycle food intake compared with saline treatment in Pomc ARC-WT mice when analyzed over the first 3 hr of the dark cycle ( Figure 6G , left) and as cumulative 3 and 6 hr of food intake ( Figure 6G , right). In contrast, Pomc ARC-CRISPR mice only significantly responded to the acute anorectic effect of lorcaserin ( Figure 6H , left). Analysis of 3-and 6-hr cumulative intake revealed that Pomc ARC-CRISPR mice exhibited an attenuated response to lorcaserin. Specifically, lorcaserin did not significantly alter food intake compared with saline treatment at either time point in Pomc ARC-CRISPR mice ( Figure 6H, right) . One interpretation of these data is that POMC ARC is not a principal mediator of lorcaserin's acute effects on food intake; rather, it is necessary for the longer-term effect. However, it is possible that the acute response to lorcaserin in Pomc ARC-CRISPR mice is due to incomplete knockdown of POMC ARC and that the subset remaining is sufficient for lorcaserin to reduce feeding at this earlier time point. Nevertheless, these data indicate that lorcaserin requires functional Pomc within the ARC to promote its full effect on food intake. Figures 7A and 7B) . Since a-MSH expression from NTS explants is not at a high enough level for reliable measurement, we adopted the method used above for Pomc ARC-CRISPR validation, allowing ex vivo detection of DNA heteroduplexes to control for the occurrence of CRISPR/Cas9-induced indels. Genomic DNA from Pomc NTS-CRISPR and Pomc NTS-WT mice was extracted and the third exon of the Pomc gene was amplified by PCR. Subsequent PAGE analysis revealed that DNA heteroduplexes were exclusively in samples obtained from the NTS/DMV and not an internal control region in Pomc NTS-CRISPR mice ( Figures 7C and 7D ). As expected, DNA heteroduplexes were not found in either the NTS/DMV or an internal control region of Pomc NTS-WT mice ( Figure 7C ). These data suggest that Pomc has been successfully targeted in Pomc NTS-CRISPR mice, although this method does not provide quantification of the degree of knockdown. As expected, lorcaserin and WAY161,503 significantly reduced ad libitum dark cycle food intake in To the right, sharing its y axis with the raw trace, are Gaussian fits of averaged (solid lines) holding current frequency distributions in control (green) and lorcaserin (blue). Raw data used to produce averages shown as dashed lines (n = 13, t 12 = 6.2, p = 4.5 3 10 À5 , t-test paired, ***p < 0.001).
POMC NTS Is Required for the Acute Effect of 5-HT 2C R Agonists on Food Intake
(E) Averaged voltage-clamp ramps (n = 12) acquired in control (green) and at the peak of response (blue). Line denotes mean, shading the SEM.
(F) Lorcaserin-induced current (I Lorcaserin ) obtained by the digital subtraction of the traces displayed in (E). Note the reversal at À24.6 ± 2.9 mV (n = 12). Line denotes mean, shading the SEM. (E) Pomc ARC-CRISPR mice exhibit 24 hr of hyperphagia for home cage chow following food restriction compared with Pomc ARC-WT mice (n = 7-8; F 1,13 = 11.27, p = 0.005).
(F) Likewise, Pomc ARC-CRISPR mice show greater motivation to work for palatable food compared with Pomc ARC-WT mice as assessed by the breakpoint of lever presses for chocolate pellets using a progressive-ratio schedule (n = 7-8; t 12 = 2.463, p = 0.029).
(G) (Left) Lorcaserin (7 mg/kg, i.p.) reduced acute food intake within the first 3 hr (tick marks on x axis represent 20-min intervals) of the dark cycle in Pomc ARC-WT mice (n = 7; time: F 9,54 = 38.05, p < 0.0001; treatment: F 1,6 = 39.94, p = 0.0007; interaction: F 9,54 = 13.91, p < 0.0001) and (right) as analyzed as total 3-and 6-hr cumulative intake (time: F 1,6 = 169.7, p < 0.0001; treatment: F 1,6 = 11.22, p = 0.0154; interaction: F 1,6 = 0.8351, p = 0.3960).
(H) (Left) Lorcaserin (7 mg/kg, i.p.) also reduced acute food intake within the first 3 hr in Pomc ARC-CRISPR mice (n = 10; time: F 9,81 = 168.1, p < 0.0001; treatment: 
Pomc
NTS-WT mice over 6 hr ( Figures 7E and 7G) . However, following administration of 5-HT 2C R agonists, Pomc NTS-CRISPR mice exhibited an attenuated anorectic response to both lorcaserin and WAY161,503 during the first 3 hr of the dark cycle ( Figure 7F ). This attenuated effect to lorcaserin and WAY161,503 did not persist for the full 6 hr in Pomc NTS-CRISPR mice. Lorcaserin significantly reduced 6-hr cumulative intake in Pomc NTS-CRISPR mice compared with saline treatment ( Figure 7H ). Taken together with the Pomc NEO and Pomc ARC-CRISPR results, these data suggest that POMC NTS is required for the acute effect of lorcaserin on food intake, whereas POMC ARC is required for the longer-term effect on feeding. These findings are generally consistent with previous reports using chemogenetic and optogenetic approaches to examine POMC neuron function, which suggest that POMC ARC and POMC NTS neurons affect feeding on different time scales (Aponte et al., 2011; Koch et al., 2015; Zhan et al., 2013) .
DISCUSSION
Obesity negatively affects human health on a global scale. If we are to meet this challenge and design new medications, it is paramount that we gain a more complete understanding of the mechanisms regulating food intake and body weight. The 5-HT 2C R agonist lorcaserin is a current obesity medication; however, neither the specific subset of 5-HT 2C Rs coordinating the therapeutic effect nor the neurochemical mediator targeted by these receptors has been fully defined. Earlier research genetically manipulating the receptor revealed that the subset of 5-HT 2C Rs co-expressed with brain POMC are both sufficient (Xu et al., 2010) and necessary (Berglund et al., 2013) to modulate the anorectic effect of preclinical 5-HT 2C R agonists. Given that 5-HT 2C R agonists increase the activity of POMC ARC neurons (Burke and Heisler, 2015; Doslikova et al., 2013; Heisler et al., 2002) , it was presumed that these neurons were the mediator of this effect. However, in light of recent findings that POMC ARC neurons suppress appetite on a time scale of hours (Aponte et al., 2011; Koch et al., 2015; Zhan et al., 2013) , we considered whether 5-HT 2C Rs outside the ARC are necessary for 5-HT 2C R's acute effects on feeding. Here we identify the function of a previously uncharacterized subset of 5-HT 2C R expressing neurons, localized within the NTS, and reveal that the activation of this subpopulation has a significant and rapid impact on feeding behavior, and furthermore is sufficient to drive lorcaserin's acute reduction in food intake. In addition, we report that a subset of POMC NTS neurons express 5-HT 2C Rs and that 5-HT and 5-HT 2C R agonists directly activate POMC NTS neurons via a post-synaptic, mixed cationic current. We also clarify that brain POMC is necessary for lorcaserin to influence feeding. Although POMC is not abundantly expressed within the NTS, we report that POMC in this region is required for 5-HT 2C R agonist obesity medications to acutely reduce food intake. These data thereby reveal a subpopulation of 5-HT 2C Rs, which when pharmacologically activated significantly reduce food intake, identify that the mechanistic underpinnings of this acute effect is via POMC NTS , and demonstrate that this discrete 5-HT 2C R NTS subpopulation is therapeutically relevant to obesity medications targeting the 5-HT 2C Rs.
Limitations of Study
It is possible that the results obtained are affected by incomplete knockdown of Pomc in the ARC and NTS. Although altering POMC NTS expression significantly attenuated the acute effect of lorcaserin on food intake, at baseline Pomc NTS-CRISPR mice displayed food intake comparable with Pomc NTS-WT mice during ad libitum feeding (Figures 7E and 7F ; and data not shown). These data are consistent with a previous report of diphtheria toxin POMC NTS cell ablation in a Pomc Cre mouse line, which did not produce an effect on ad libitum food intake (Zhan et al., 2013) . However, we cannot exclude the possibility that this absence of baseline phenotype Pomc NTS-CRISPR mice is due to incomplete knockdown of Pomc NTS . Further studies are required to fully interrogate the physiological role of POMC NTS . Nevertheless, our data reveal that the relatively small source of POMC specifically derived within the NTS is necessary for the obesity medication lorcaserin and the preclinical compound WAY161,503 to promote their full effects on feeding behavior.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
5-HT 2C R-ires
Cre Marcinkiewcz et al., 2016) , loxtb5-HT 2C R (B6.129-Htr2c tm1Jke /J; The Jackson Laboratory, Bar
Harbor, ME USA), Pomc DsRED (Hentges et al., 2009) and Pomc NEO (Bumaschny et al., 2012) mice were housed with ad libitum food and water access (unless otherwise stated) in a light-(12 h on/12 h off) and temperature-controlled (21.5 C to 22.5 C) environment. All procedures were performed in accordance with the U.K. Animals (Scientific Procedures) Act 1986 and local ethical approvals.
METHOD DETAILS
Stereotaxic Surgery and Viral Vectors Viral constructs were packaged in AAV serotype-8 and were delivered to the NTS via bilateral stereotaxic injections, as previously described .
AAV vectors
The DREADD viruses used have been described previously: AAV8-hSyn-DIO-hM3D q -mCherry, AAV8-hSyn-DIO-hM4D i -mCherry and AAV8-hSyn-mCherry-Cre were packaged in AAV serotype-8 at a titer of 1.3 x 10 13 vg/ml (University North Carolina Vector microinjections over 4-5 minutes. The pipette remained in place for a minimum of 3 minutes after injection. Following all surgery, animals were closely monitored, kept warm and appropriate postsurgical care was taken. Animals were also administered an analgesic (5 mg/kg carprofen, s.c.) daily for 2 days post-operatively. Prior to experimentation, mice were acclimated to handling and i.p. injections. Mice were given a minimum of 14 days of surgical recovery before experimentation. For chemogenetic experiments, mCherry was visualised by immunohistochemistry. Mice in which the expression of reporter fluorescent protein was bilaterally detected in the caudal aspect of the DVC were included in the analysis, whereas mice without reporter fluorescent expression or expression outside the DVC were excluded from the analysis. Caudal DVC was defined by the presence of the area postrema in the same section of brain tissue. DNA Constructs For SpCas9 target selection and generation of single guide RNA (sgRNA), the 20-nt target sequences were selected to precede a 5'-NGG protospacer-adjacent motif (PAM) sequence. To minimize off-targeting effects, the CRISPR design tool was used (http:// crispr.mit.edu/). The 20-nt target and complement sequences were synthesized to include BbsI overhangs. Oligos were annealed, phosphorylated and ligated into the pX330-U6-Chimeric_BB-CBh-hSpCas9 (PX330; Addgene plasmid #42230) plasmid after BbsI digestion.
pAAV-U6sgRNA(SapI)_hSyn-GFP-KASH-bGH (PX552; Addgene plasmid # 60958) was used for cloning sgRNAs into AAV the backbone and generate viral particles. The plasmid was first digested with SapI to create sticky ends for ligation. The 20-nt target and complement sequences were synthesized to include SapI overhangs and ligated. A second sgRNA was then inserted into this vector. The second sgRNA was first PCR-amplified from PX330. Primers were designed to include 15bp homology arms to the PspOMI-lineraised PX552 into the PCR clone sgRNA guide. The PCR product was column-purified and then cloned into the PspOMI-lineraised PX552 vector via homologous recombination-assisted cloning (In-Fusion HD cloning KitÒ, Cat No. 638910; Clonotech Laboratories). Primers sequences: AGACTGCAGAGGGCCGAGGGCCTATTTCCCATGATTCCT, forward; CTCATACGCAGG GCCCTAAAACAAAAAAGCACCGACTCGG, reverse. All obtained constructs were verified by sequencing. All plasmids were amplified using One ShotÒ Stbl3Ô Chemically Competent E. coli (Cat No. C737303; Invitrogen) and column-purified (Cat No. 270104; Qiagen) .
Pomc targeting sgRNAs (5' to 3'): sgRNA 1-GGTGGGCAAGAAACGGCGCC(cgg); sgRNA 2-GTGACCCATGACGTACTTC CG(ggg). Cell Line Culture and Transfection Mouse Neuro-2a (N2a) cells were grown in DMEM containing 10% FBS. Cells were maintained at 37 C in 5% CO 2 atmosphere. Transfection were performed using FuGENE Ò HD Transfection Reagent (Cat No E2311; Promega) according to the manufacturer's protocol. Briefly, 1.5x10 4 cells per well were plated into a 12 well plate the day before transfection. 1 ug of PX330 plasmid was mixed with Fugene HD in Optimem medium (ratio 1:3). Cells were incubated for 48 hours. Genomic DNA was extracted from transfected cells using PureLinkÒ Genomic DNA Mini Kit (Cat No K182001, Invitrogen) following the manufacturer's instructions. Detection of Insertions/Deletions (Indels) The third exon of the mouse Pomc gene was PCR amplified from genomic DNA using the following primers: GCTTGCATC CGGGCTTGC, forward; GACTTTATTTACGCAGTTTTTATTGAAGATCAGAGC, reverse. This PCR reaction generates a single PCR product of the expected 726bp size. PCR product was sequence verified. To detect sgRNA/spCas9-induced indels, genomic DNA from cells was amplified using the same primers and this 726bp product corresponding to third exon of the mouse Pomc gene was used for the endonuclease I assay (SurveyorÒ Mutation Detection Kit; Cat No. 706020; Integrated DNA Technologies) following the manufacturer's instructions. Briefly, PCR amplicons were heat-denaturated and re-annealed using a thermocycler to create DNA heteroduplexes. DNA heteroduplexes were incubated with endonuclease I enzyme, which cleaves DNA at the site of a base mismatch with high specificity, for 1 hour at 42 C. Genomic modifications were verified using gel agarose electrophoresis.
Feeding Studies
Dark Cycle Food Intake Mice were injected with vehicle or drug 30 minutes prior to the onset of the dark cycle and food was removed. At the onset of dark, food was returned and manually (home cage) or automatically (Phenomaster chambers, TSE, Bad Homburg, Germany) weighed using methods previously described .
Post-fast Refeeding
Food was removed at the onset of the dark cycle and returned 2 hours after the onset of the light cycle the following day. Food intake was measured manually (home cage) or automatically (TSE Phenomaster chambers) using methods previously described . Progressive Ratio Mice were trained in operant chambers housed in sound-attenuating boxes and controlled by a PC Med-PC-IV programming language (MED Associates, Inc., Fairfax, VT USA). Chambers (21.6 cm long 3 17.8 cm wide 3 12.7 cm high) have a retractable lever, a pellet receptacle and a 3 watt house-light on the opposite wall (Cat No. MED-307W-D1, MED Associates, Inc.). Under food restriction, mice were trained to press the lever for 20 mg chocolate pellet reinforcers (TestDiet, St. Louis, MO USA) under a fixed ratio (FR) 1 schedule for 3 days followed by FR 5 for a further 3 days. Then they were fed ad libitum and underwent daily training under a PR schedule based on an exponential progression derived from the formula (5 3 e0.2n)À5, rounded to the nearest integer,
